Advertisement

Cancer Causes & Control

, Volume 24, Issue 5, pp 949–960 | Cite as

Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand

  • Michelle C. Turner
  • Daniel Krewski
  • Bruce K. Armstrong
  • Angela Chetrit
  • Graham G. Giles
  • Martine Hours
  • Mary L. McBride
  • Marie-Élise Parent
  • Siegal Sadetzki
  • Jack Siemiatycki
  • Alistair Woodward
  • Elisabeth Cardis
Original paper

Abstract

Purpose

A history of allergy has been inversely associated with several types of cancer although the evidence is not entirely consistent. We examined the association between allergy history and risk of glioma, meningioma, acoustic neuroma, and parotid gland tumors using data on a large number of cases and controls from five INTERPHONE study countries (Australia, Canada, France, Israel, New Zealand), to better understand potential sources of bias in brain tumor case–control studies and to examine associations between allergy and tumor sites where few studies exist.

Methods

A total of 793 glioma, 832 meningioma, 394 acoustic neuroma, and 84 parotid gland tumor cases were analyzed with 2,520 controls recruited during 2000–2004. Conditional logistic regression models were used to obtain odds ratios (ORs) and 95 % confidence intervals (CIs) for associations between self-reported allergy and tumor risk.

Results

A significant inverse association was observed between a history of any allergy and glioma (OR = 0.73, 95 % CI 0.60–0.88), meningioma (OR = 0.77, 95 % CI 0.63–0.93), and acoustic neuroma (OR = 0.64, 95 % CI 0.49–0.83). Inverse associations were also observed with specific allergic conditions. However, inverse associations with asthma and hay fever strengthened with increasing age of allergy onset and weakened with longer time since onset. No overall association was observed for parotid gland tumors (OR = 1.21, 95 % CI 0.73–2.02).

Conclusions

While allergy history might influence glioma, meningioma, and acoustic neuroma risk, the observed associations could be due to information or selection bias or reverse causality.

Keywords

Asthma Hay fever Eczema Glioma Meningioma Acoustic neuroma 

Notes

Acknowledgments

Funding for the INTERPHONE Study was provided by the European Fifth Framework Program, ‘Quality of Life and Management of Living Resources’ (contract QLK4-CT-1999901563), the International Union against Cancer (UICC). The UICC received funds for this purpose from the Mobile Manufacturers’ Forum and GSM Association. Provision of funds to the INTERPHONE Study investigators via the UICC was governed by agreements that guaranteed INTERPHONE’s complete scientific independence. The terms of these agreements are publicly available at http://www.iarc.fr/en/research-groups/RAD/RCAd.html. The Australian center was supported by the National Health and Medical Research Council (EME grant 219129); BKA was supported by a University of Sydney Medical Foundation Program Grant. The Cancer Council NSW and the Cancer Council Victoria provided most of the infrastructure for the project in Australia. The Canada-Montreal data collection was funded by a grant from the Canadian Institutes of Health Research (CIHR) (project MOP-42525). Additionally, JS’s research team was partly funded by the Canada Research Chair programme and by the Guzzo-CRS Chair in Environment and Cancer. The other Canadian centers were supported by a university-industry partnership grant from the CIHR, the latter including partial support from the Canadian Wireless Telecommunications Association. The CIHR university-industry partnerships program also includes provisions that ensure complete scientific independence of the investigators. DK is the Natural Sciences and Engineering Research Council (NSERC) Chair in Risk Science at the University of Ottawa. Additional funding for the study in France was provided by l’Association pour la Recherche sur le Cancer (ARC) (contract 5142) and three network operators (Orange, SFR, Bouygues Telecom). The funds provided by the operators represented 5 % of the total cost of the French study and were governed by contracts guaranteeing the complete scientific independence of the investigators. In New Zealand, funding was provided by the Health Research Council, Hawkes Bay Medical Research Foundation and the Cancer Society of New Zealand. The authors would like to acknowledge Jordi Figuerola (CREAL) for programming and database management support. The Australian team would like to acknowledge the overall support given to study design and implementation by Michael Besser and Andrew Kaye; and to thank fieldwork staff in Melbourne—Monique Kilkenny, Georgina Marr, Tracey McPhail, Fiona Phillips, Hayley Shaw, Yvonne Torn-Broers; and Sydney—Matthew Carroll, Sally Dunlop, Virginia MacDonald and Elizabeth Willows—the many interviewers for their hard work, and the NSW and Victorian Cancer Registries for aiding case identification. We also thank Angus Cook (University of Western Australia) and Neil Pearce (London School of Hygiene and Tropical Medicine) who, together with Alistair Woodward, were responsible for the conduct of the INTERPHONE Study in New Zealand. The Canada-Ottawa center gratefully acknowledges the work of Lynn Pratt and Daniel Bedard for their leading roles in study coordination. The Canada-Montreal team acknowledges Louise Nadon and the diligent work of fieldwork staff including Marie-Claire Goulet, Sylvie Plante, Sally Campbell, and the interviewer team. The following hospitals and physicians in Montreal permitted access to their patients: CHUM Hopital Notre-Dame (Dr Wieslaw Michel Bojanowski, Dr Jean Jacques Dufour, Dr Francois Lavigne, Dr Robert A Moumdjian); Neurological Institute of Montreal (Dr Rolando Del Maestro, Dr Richard Leblanc); Hopital du Sacre-Coeur de Montreal (Dr Marc F Giroux); The Jewish General Hospital (Dr Gerard Mohr, Dr Jamie Miles Rappaport). The Canada-Vancouver center wishes to acknowledge the work carried out by Dr Alison Pope, Patricia Nelson, Nelson Ha, Dr Kaushik Bhagat and the interviewer team. The French team to thank the French fieldwork team, Mary-Pierre Herrscher, Fatima Lamri, Agnes Boidart, Helene Gire, Juliette Krassilchik, Judith Lenti, Delphine Maillac, Frederique Sonnet, Flore Taguiev, Julie Frantz, France Castay, Florian Gay, for their excellent work. The Israeli team acknowledges the diligent work of the fieldwork and office staff including Etti Aviezer, Tehila Ben-Tal, Meirav Dolev, Yonit Deutch, Tamara Rodkin, Ahuva Zultan and the interviewer team.

Conflict of interest

The authors have no conflict of interest to declare.

References

  1. 1.
    Turner MC (2012) Epidemiology: allergy history, IgE and cancer. Cancer Immunol Immunother 61:1493–1510PubMedCrossRefGoogle Scholar
  2. 2.
    Linos E, Raine T, Alosno A, Michaud D (2007) Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 99:1544–1550PubMedCrossRefGoogle Scholar
  3. 3.
    Berg-Beckhoff G, Schuz J, Blettner M, Munster E, Schlaefer K, Wahrendorf J, Schlehofer B (2009) History of allergic disease and epilepsy and risk of glioma and meningioma (INTERPHONE study group, Germany). Eur J Epidemiol 24:433–440PubMedCrossRefGoogle Scholar
  4. 4.
    Schlehofer B, Schlaefer K, Blettner M, Berg G, Bohler E, Hettinger I, Kunna-Grass K, Wahrendorf J, Schuz J, Interphone Study Group (2007) Environmental risk factors for sporadic acoustic neuroma (Interphone Study Group, Germany). Eur J Cancer 43:1741–1747PubMedCrossRefGoogle Scholar
  5. 5.
    Schoemaker MJ, Swerdlow AJ, Hepworth SJ, McKinney PA, van Tongeren M, Muir KR (2006) History of allergies and risk of glioma in adults. Int J Cancer 119:2165–2172PubMedCrossRefGoogle Scholar
  6. 6.
    Schoemaker MJ, Swerdlow AJ, Hepworth SJ, van Tongeren M, Muir KR, McKinney PA (2007) History of allergic disease and risk of meningioma. Am J Epidemiol 165:477–485PubMedCrossRefGoogle Scholar
  7. 7.
    Wigertz A, Lonn S, Schwartzbaum J, Hall P, Auvinen A, Christensen HC, Johansen C, Klaeboe L, Salminen T, Schoemaker MJ, Swerdlow AJ, Tynes T, Feychting M (2007) Allergic conditions and brain tumor risk. Am J Epidemiol 166:941–950PubMedCrossRefGoogle Scholar
  8. 8.
    Schoemaker MJ, Swerdlow AJ, Auvinen A, Christensen HC, Feychting M, Johansen C, Klaeboe L, Lonn S, Salminen T, Tynes T (2006) Medical history, cigarette smoking and risk of acoustic neuroma: an international case–control study. Int J Cancer 120:103–110CrossRefGoogle Scholar
  9. 9.
    Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodriguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H (2008) AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 63:1255–1266PubMedCrossRefGoogle Scholar
  10. 10.
    Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Lonn S, Soderberg KC, Feychting M (2003) Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 106:423–428PubMedCrossRefGoogle Scholar
  11. 11.
    Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, Calle EE (2005) Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 162:212–221PubMedCrossRefGoogle Scholar
  12. 12.
    Cardis E, Richardson L, Deltour I, Armstrong B, Feychting M, Johansen C, Kilkenny M, McKinney P, Modan B, Sadetzki S, Schuz J, Swerdlow A, Vrijheid M, Auvinen A, Berg G, Blettner M, Bowman J, Brown J, Chetrit A, Christensen HC, Cook A, Hepworth S, Giles G, Hours M, Iavarone I, Jarus-Hakak A, Klaeboe L, Krewski D, Lagorio S, Lonn S et al (2007) The INTERPHONE study: design, epidemiological methods, and description of the study population. Eur J Epidemiol 22:647–664PubMedCrossRefGoogle Scholar
  13. 13.
    Cardis E, Armstrong BK, Bowman JD, Giles GG, Hours M, Krewski D, McBride M, Parent ME, Sadetzki S, Woodward A, Brown J, Chetrit A, Figuerola J, Hoffmann C, Jarus-Hakak A, Montestruq L, Nadon L, Richardson L, Villegas R, Virjheid M (2011) Risk of brain tumours in relation to estimated RF dose from mobile phones: results from five Interphone countries. Occup Environ Med 68:631–640PubMedCrossRefGoogle Scholar
  14. 14.
    SAS Institute, Inc (2008) SAS, version 9.2. SAS Institute, Inc., CaryGoogle Scholar
  15. 15.
    Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A, Ahlbom A, Choi WN, Giles GG, Howe GR, Little J, Menegoz F, Ryan P (1999) Role of medical history in brain tumor development. Results from the International Adult Brain Tumor Study. Int J Cancer 82:155–160PubMedCrossRefGoogle Scholar
  16. 16.
    McCarthy BJ, Rankin K, Il’yasova D, Erdal S, Vick N, Ali-Osman F, Bigner DD, Davis F (2011) Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol Biomarkers Prev 20:370–378PubMedCrossRefGoogle Scholar
  17. 17.
    Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD (2002) History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 99:252–259PubMedCrossRefGoogle Scholar
  18. 18.
    Wiemels JL, Wiencke JK, Patoka J, Moghadassi M, Chew T, McMillan A, Miike R, Barger G, Wrensch M (2004) Reduced immunoglobulin E and allergy among adults with glioma compared with controls. Cancer Res 64:8468–8473PubMedCrossRefGoogle Scholar
  19. 19.
    Schwartzbaum JA, Huang K, Lawler S, Ding B, Yu J, Chiocca EA (2010) Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol 12:320–327PubMedCrossRefGoogle Scholar
  20. 20.
    Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V (2011) Mechanisms of immunomodulation in human glioblastoma. Immunotherapy 3(4 Suppl):42–44PubMedCrossRefGoogle Scholar
  21. 21.
    Anto JM, Pinart M, Akdis M, Auffray C, Bachert C, Basagana X, Carlsen KH, Guerra S, von Hertzen L, Illi S, Kauffmann F, Keil T, Kiley JP, Koppelman GH, Lupinek C, Martinez FD, Nawijn MC, Postma DS, Siroux V, Smit HA, Sterk PJ, Sunyer J, Valenta R, Valverde S, Akdis CA, Annesi-Maesano I, Ballester F, Benet M, Cambon-Thomsen A, Chatzi L et al (2012) Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: a mechanisms of the development of allergy (MeDALL) seminar. J Allergy Clin Immunol 129:943–954PubMedCrossRefGoogle Scholar
  22. 22.
    Novak N, Bieber T (2003) Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 112:252–262PubMedCrossRefGoogle Scholar
  23. 23.
    Il’yasova D, McCarthy B, Marcello J, Schildkraut JM, Moorman PG, Krishnamachari B, Ali-Osman F, Bigner DD, Davis F (2009) Association between glioma and history of allergies, asthma, and eczema: a case–control study with three groups of controls. Cancer Epidemiol Biomarkers Prev 18:1232–1238PubMedCrossRefGoogle Scholar
  24. 24.
    Wiemels JL, Wrensch M, Sison JD, Zhou M, Bondy M, Calvocoressi L, Black PM, Yu H, Schildkraut JM, Claus EB (2011) Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls. Int J Cancer 129:1932–1939PubMedCrossRefGoogle Scholar
  25. 25.
    Wiemels JL, Wilson D, Patil C, Patoka J, McCoy L, Rice T, Schwartzbaum J, Heimberger A, Samson JH, Chang S, Prados M, Wiencke JK, Wrensch M (2009) IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era. Int J Cancer 125:680–687PubMedCrossRefGoogle Scholar
  26. 26.
    Calboli FC, Cox DG, Buring JE, Gaziano JM, Ma J, Stampfer M, Willett WC, Tworoger SS, Hunter DJ, Camargo CA Jr, Michaud DS (2011) Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies. J Natl Cancer Inst 103:1588–1595PubMedCrossRefGoogle Scholar
  27. 27.
    Schlehofer B, Siegmund B, Linseisen J, Schuz J, Rohrmann S, Becker S, Michaud D, Melin B, Bas Bueno-de-Mesquita H, Peeters PH, Vineis P, Tjonneland A, Olsen A, Overvad K, Romieu I, Boeing H, Aleksandrova K, Trichopoulou A, Bamia C, Lagiou P, Sacerdote C, Palli D, Panico S, Sieri S, Tumino R, Sanchez MJ, Rodriguez L, Dorronsoro M, Duell EJ, Chirlaque MD et al (2011) Primary brain tumours and specific serum immunoglobulin E: a case–control study nested in the European prospective investigation into cancer and nutrition cohort. Allergy 66:1434–1441PubMedCrossRefGoogle Scholar
  28. 28.
    Schwartzbaum J, Ding B, Johannesen TB, Osnes LTN, Karavodin L, Ahlbom A, Feychting M, Grimsrud TK (2012) Association between prediagnostic IgE levels and risk of glioma. J Natl Cancer Inst 104:1251–1259PubMedCrossRefGoogle Scholar
  29. 29.
    Carosso A, Bugiani M, Migliore E, Anto JM, DeMarco R (2007) Reference values of total serum IgE and their significance in the diagnosis of allergy in young European adults. Int Arch Allergy Immunol 142:230–238PubMedCrossRefGoogle Scholar
  30. 30.
    Hoppin JA, Jaramillo R, Salo P, Sandler DP, London SJ, Zeldin DC (2011) Questionnaire predictors of atopy in a US population sample: findings from the National Health and Nutrition Examination Survey, 2005–2006. Am J Epidemiol 173:544–552PubMedCrossRefGoogle Scholar
  31. 31.
    Zhou M, Wiemels JL, Bracci PM, Wrensch MR, McCoy LS, Rice T, Sison JD, Patoka JS, Wiencke JK (2010) Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma. Cancer Res 70:7534–7542PubMedCrossRefGoogle Scholar
  32. 32.
    Dobbins SE, Hosking FJ, Shete S, Armstrong G, Swerdlow A, Liu Y, Yu R, Lau C, Schoemaker MJ, Hepworth SJ, Miur K, Bondy M, Houlston RS (2011) Allergy and glioma risk: test of association by genotype. Int J Cancer 128:1736–1740PubMedCrossRefGoogle Scholar
  33. 33.
    Lachance DH, Yang P, Johnson DR, Decker PA, Kollmeyer TM, McCoy LS, Rice T, Xiao Y, Ali-Osman F, Wang F, Stoddard SM, Sprau DJ, Kosel ML, Wiencke JK, Wiemels JL, Patoka JS, Davis F, McCarthy B, Rynearson AL, Worra JB, Fridley BL, O’Neill BP, Buckner JC, Il’yasova D, Jenkins RB, Wrensch MR (2011) Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. Am J Epidemiol 174:574–581PubMedCrossRefGoogle Scholar
  34. 34.
    Ruan Z, Zhao Y, Yan L, Chen H, Fan W, Chen J, Wu Q, Qian J, Zhang T, Zhou K, Mao Y, Zhou L, Huang Y, Lu D (2011) Single nucleotide polymorphisms in Il-4Ra, IL-13 and STAT6 genes occurs in brain glioma. Front Biosci (Elite Ed) 3:33–45CrossRefGoogle Scholar
  35. 35.
    Schoemaker MJ, Robertson L, Wigertz A, Jones ME, Hosking FJ, Feychting M, Lonn S, McKinney PA, Hepworth SJ, Muir KR, Auvinen A, Slaminen T, Kiuru A, Johansen C, Houlston RS, Swerdlow AJ (2010) Interaction between 5 genetic variants and allergy in glioma risk. Am J Epidemiol 171:1165–1173PubMedCrossRefGoogle Scholar
  36. 36.
    Schwartzbaum J, Ahlbom A, Malmer B, Lonn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M (2005) Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res 65:6459–6465PubMedCrossRefGoogle Scholar
  37. 37.
    Schwartzbaum JA, Ahlbom A, Lonn S, Malmer B, Wigertz A, Auvinen A, Brookes AJ, Collatz CH, Henriksson R, Johansen C, Salminen T, Schoemaker MJ, Swerdlow AJ, Debinski W, Feychting M (2007) An international case–control study of interleukin-4Ra, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev 16:2448–2454PubMedCrossRefGoogle Scholar
  38. 38.
    Wiemels JL, Wiencke JK, Kelsey KT, Moghadassi M, Rice T, Urayama KY, Miike R, Wrensch M (2007) Allergy-related polymorphisms influence glioma status and serum IgE levels. Cancer Epidemiol Biomarkers Prev 16:1229–1235PubMedCrossRefGoogle Scholar
  39. 39.
    Linabery AM, Jurek AM, Duval S, Ross JA (2010) The association between atopy and childhood/adolescent leukemia: a meta-analysis. Am J Epidemiol 171:749–764PubMedCrossRefGoogle Scholar
  40. 40.
    Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, Weinberg JS, Bondy ML (2008) Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev 17:1277–1281PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Michelle C. Turner
    • 1
    • 2
    • 3
  • Daniel Krewski
    • 1
    • 4
    • 5
  • Bruce K. Armstrong
    • 6
  • Angela Chetrit
    • 7
  • Graham G. Giles
    • 8
    • 9
  • Martine Hours
    • 10
  • Mary L. McBride
    • 11
  • Marie-Élise Parent
    • 12
  • Siegal Sadetzki
    • 7
    • 13
  • Jack Siemiatycki
    • 14
  • Alistair Woodward
    • 15
  • Elisabeth Cardis
    • 2
    • 3
  1. 1.McLaughlin Centre for Population Health Risk Assessment, Institute of Population HealthUniversity of OttawaOttawaCanada
  2. 2.Centre for Research in Environmental Epidemiology (CREAL)BarcelonaSpain
  3. 3.CIBER Epidemiología y Salud Pública (CIBERESP)BarcelonaSpain
  4. 4.Department of Epidemiology and Community Medicine, Faculty of MedicineUniversity of OttawaOttawaCanada
  5. 5.Risk Sciences InternationalOttawaCanada
  6. 6.Sydney School of Public HealthThe University of SydneySydneyAustralia
  7. 7.Cancer and Radiation Epidemiology Unit, The Gertner Institute for Epidemiology and Health Policy ResearchChaim Sheba Medical CentreTel-HashomerIsrael
  8. 8.Cancer Epidemiology CentreCancer Council VictoriaMelbourneAustralia
  9. 9.Centre for MEGA Epidemiology, School of Population HealthThe University of MelbourneMelbourneAustralia
  10. 10.Unité Mixte de Recherche Epidémiologique Transport Travail Environnement IFSTTAR, UCBLUniversité Lyon 1 IFSTTARLyonFrance
  11. 11.Cancer Control ResearchBritish Columbia Cancer AgencyVancouverCanada
  12. 12.INRS-Institut Armand-FrappierUniversité du QuébecLavalCanada
  13. 13.Sackler School of MedicineTel-Aviv UniversityTel-AvivIsrael
  14. 14.CRCHUMUniversity of MontrealMontrealCanada
  15. 15.School of Population HealthUniversity of AucklandAucklandNew Zealand

Personalised recommendations